AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03085407 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: delayed cholecystectomy
Description: cholecystectomy was done after 30 days after randomization
Study NCT04200287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online decision aid tool
Description: The decision aid intervention will be presented via a website
Study NCT03358433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT03304639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04233645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-minute educational video
Description: The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
Study NCT04233645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The groups will be given a standard scripted verbal and identical written instructions as per usual care.
Study NCT03304639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02777398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Quadrant Channel Surgery
Description: Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
Study NCT02339571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02339571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02339571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02339571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02339571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI
Study NCT02339571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04233645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The groups will be given a standard scripted verbal and identical written instructions as per usual care.
Study NCT04380168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified pec11 trunk block
Description: Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
Study NCT04077983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy using nab-paclitaxel and gemcitabine chemotherapy
Description: 1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses.
Study NCT02777398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Open Surgery
Description: Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
Study NCT00497913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study NCT03481322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cooked diet with controlled amount of salt
Description: Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
Study NCT03481322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cooked diet with controlled amount of salt
Description: Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg atorvastatin
Description: 10mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg atorvastatin
Description: 10mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 80mg atorvastatin
Description: 80mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg atorvastatin
Description: 80mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80mg atorvastatin
Description: 80mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263 Placebo
Description: Placebo
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg GSK1292263
Description: 100mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg GSK1292263
Description: 300mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg GSK1292263
Description: 800mg
Study NCT01218204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg ezetimibe
Description: 10mg
Study NCT01218204 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Washout
Description: No interventions - washout period
Study NCT01141907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Self Care Support
Description: The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
Study NCT01141907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual heart failure care
Description: Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
Study NCT03090113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection
Description: intravenous drip
Study NCT02339571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00497913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Study NCT03349801 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: According to clinical practice.
Study NCT01942668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01942668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03090113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: intravenous drip
Study NCT00585819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reproduce breathing cycle utilizing spirometry
Description: reproduce breathing cycle utilizing spirometry
Study NCT00585819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freebreathing in Body fix mold
Description: Freebreathing in Body fix mold
Study NCT02852408 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Study NCT04675840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted hysterectomy
Description: Robotic-assisted surgery
Study NCT03905603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: ACTH (Cosyntropin) 250 mcg will be given once during the study.
Study NCT03905603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: rhCG (Ovidrel) 250 mcg will be given once during the study.
Study NCT02759328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ training
Description: Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
Study NCT02759328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
Study NCT01987505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg will be injected subcutaneously (SC).
Study NCT03795987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
Study NCT00294268 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive behavioural therapy
Description: 20 weekly sessions of CBT integrated with motivational enhancement strategies
Study NCT03489447 — intervention group
Intervention type: OTHER
Intervention: ICU care
Description: exposure to ICU treatment with or without diagnosed sepsis
Study NCT04224649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARA Filler(Hyaluronic acid Filler)
Description: The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
Study NCT04224649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane® Lidocaine
Description: The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
Study NCT02339571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT01749514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
Study NCT04693273 — intervention group
Intervention type: OTHER
Intervention: Decision Aid for Surgical Modality Choice
Description: A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
Study NCT01540630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Description: CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
Study NCT01540630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo comparator for 28 days.
Study NCT03358433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01183767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin-Gallate
Description: EGCG in a dosage of up to 10mg/kg body weight
Study NCT01183767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00860236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycoeducation/counseling
Description: 2 days of education on mechanisms of illness and coping strategies
Study NCT00860236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: 4 days intensive training in understanding and behavioural changes
Study NCT02334917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical wound closure with superficial absorbable sutures
Description: Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
Study NCT02599207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sibling umbilical cord blood
Description: All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
Study NCT04150666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Description: the same with arm descriptions
Study NCT00984165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single fraction radiation
Description: 8-Gy fraction of radiation
Study NCT00984165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single fraction radiation
Description: 8-Gy fraction of radiation
Study NCT00984165 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Unmanipulated Donor Lymphocyte Infusion
Study NCT00984165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Unmanipulated Donor Lymphocyte Infusion
Study NCT00984165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Description: Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
Study NCT04030546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine capsule
Study NCT01242696 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary artery stenting
Description: Coronary artery stenting with drug eluting stents
Study NCT03695627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute a day, 8 week digital meditation
Study NCT00798629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell-adenovirus CCL21 vaccine
Description: Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
Study NCT04147390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescribe topical 0.03 % tacrolimus
Description: prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
Study NCT04147390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescribe mycophenolate mofetil(MMF)
Description: MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
Study NCT02533427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily
Study NCT02533427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily
Study NCT05750043 — intervention group
Intervention type: DRUG
Intervention: bi-annual CDTI
Description: bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention
Study NCT03608293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Broncho Alveolar Lavages (BAL)
Description: BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
Study NCT03608293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Broncho Alveolar Lavages (BAL)
Description: BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
Study NCT02533427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate/ethinyl estradiol
Description: Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Collection
Description: Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Collection
Description: Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine Collection
Description: Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Collection
Description: During surgical tumor removal, a tumor tissue sample will be collected
Study NCT03998189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical History Data Collection
Description: Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
Study NCT03846011 — intervention group
Intervention type: OTHER
Intervention: 24-h urine collection
Description: Collecting 24-h urine prior and after stone removal surgery
Study NCT02657174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser in auricular acupuncture points
Description: 40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
Study NCT02657174 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser device off in auricular acupuncture points
Description: 40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
Study NCT01324765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARGET
Description: 12-session group therapy twice weekly 6 weeks
Study NCT01324765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: 12 sessions supportive group therapy twice weekly 6 weeks
Study NCT02736851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based telemedicine group
Description: All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period.